Besides, cilengitide enhances the function of CD8+ T cells when combined with anti-PD1 monoclonal antibody in B16 murine melanoma model, providing a promising therapeutic method for improving the response rate to immunotherapy. This evidence concerns the gene PDCD1 and melanoma.